While Cytori is getting unreimbursed approval for a stem cell clinic in japan for OA, Other companies are doing big deals. The latest is the Tigenix
. Cytori should be way more advanced in Japan based on its presence there for so long.
The following user(s) said Thank You: myownhedgefund
Cytori should be a lot of things but they are nothing but a bottomless pit of wasted invested $'s with nothing to show for it.
Money talks and bullshit walks. What we have here is all the bullshit anyone could want with zero to show for it.
Very pleased for my only other stock beyond Cytori and well deserved. To me they cash 50 Mio Euro or 55 Mio$ upfront, since the Marketing Approval of EMA should be a non-event and absolutely assured. And this for roughly 50% of the market. That is OK I guess in view of the difficult time for all stem cell outfits at present.
Hopefully the beginning of a change although the market reaction is very much lukewarm in my view. Euro 1,05 at present whilst 0,83 before the news.
Tigenix has approx. 205 Mio shares OS and has plans for an IPO on Nasdaq. I think that is a mistake, since SC stocks are clearly manipulated there.
Just for completeness sake- Tigenix gave up on Chondroselect- the approved knee cultured product, sinc old tech and not competitive.
Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology.